AxoGen, Inc. (AXGN)

[Bruce the Stock Guy]

$AXGN..So STRONG!

[Bruce the Stock Guy]

$100<<<<AXGN..I can see it..Its a one of kind company!

[Prudent Capitalist]

+18% today due to the positive earnings report and surprise and the beat on revenues. Someone here a few years back predicted AXGN would go to $100 and they are in all likelihood correct. Longer term it will exceed that level, IMO.

[Bruce the Stock Guy]

AXGN..We met a big cheese and his wife on vacation when he told us about this amazing company..

[Prudent Capitalist]

Our little GEM here has held up pretty well over the course of the pullback and recovery. We are still just in the very early stages of this company and investment.

[Bruce the Stock Guy]

AXGN..This company is just WOW..Up 600% in about a year and much more in the tank..

[Prudent Capitalist]

AxoGen ( AXGN ) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

AxoGen's platform for nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

[rajaram46]

What is thesis behind AXGN? Any good sources of information, both positive and negative?

Just heard of the company...

[Prudent Capitalist]

Agree. AXGN is a unique GEM and has lots more upside and room to run based on the fundamentals and strategic position.

[jimmybob]

This stock reminds me on NVRO before folks took notice... difference here is this could be 6-8 years of ramp/runway with no competitors...

[jimmybob]

ALACHUA, Fla., Jan. 08, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full year 2017 revenue and selected business highlights for the quarter and year ended December 31, 2017.

Preliminary Revenue and Selected Business Highlights

Fourth quarter revenue is expected to be at least $16.5 million, up 45% compared to the fourth quarter of 2016 revenue of $11.4 million
Full year 2017 revenue is expected to be at least $60.0 million, up 46% compared to 2016 revenue of $41.1 million
Ended the quarter with 60 direct sales representatives and 20 independent distributors
Completed 15 national education programs in 2017 and expect to conduct 18 programs in 2018
“We are pleased to report another successful quarter and a solid finish to 2017,” said Karen Zaderej, president and CEO of AxoGen. “These results reflect the strength of our growing platform for nerve repair where we see continued momentum in our core trauma, nerve protection and oral and maxillofacial markets. We enter 2018 with an expanding sales force that will allow us to continue growth in our core markets while also supporting our newest application in breast reconstruction neurotization.”

2017 Financial Guidance
Management increases its full year 2017 revenue guidance to at least $60.0 million. Management reiterates its full year 2017 gross margin guidance to exceed 80%.

2018 Financial Guidance
Management reiterates 2018 annual revenue will grow at least 40% over 2017 revenue and gross margins will remain above 80%.

Upcoming Investor Event

Members of the AxoGen senior management team will participate in The Trout Group Annual 1-on-1 Management Access Event in San Francisco, January 8–10, 2018. To request a meeting, please contact [e-mail].
AxoGen will also participate in the Leerink 7th Annual Global Healthcare Conference in New York City, February 14, 2018.
The results disclosed in this press release are preliminary and unaudited. The Company will report full, audited results for the fourth quarter and year ended December 31, 2017 on February 28, 2018.

[crudeoil24]

30.90 hod

[crudeoil24]

Lot of option traders entering! Market in general really taking notice today.

[Prudent Capitalist]

I first acquired AXGN shares in one of my retirement accounts in the $4.00 range. Has been a great investment and I will not be selling any of my AXGN shares any time soon. Great to have you around here on the Board.

[crudeoil24]

Plus a possible take over target!

[crudeoil24]

52 WEEK HIGHS EVERY DAY!!!!!

AXGN

[crudeoil24]

AxoGen's platform for nerve repair features a comprehensive portfolio of products, including Avance(R) Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard(R) Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard(R) Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive(R) Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal(R) Neurosensory & Motor Testing System and AxoTouch(R) Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

[crudeoil24]

AXGN going gangbusters!

[Prudent Capitalist]

Axogen featured again on a Rose Bowl float this year.

[Prudent Capitalist]

Jeffries: BUY recommendation and $35 price Target for Axogen

[Prudent Capitalist]

AxoGen Price Target Raised to $30.00/Share From $26.00 by Leerink Swann

[Prudent Capitalist]

Closed above $26 today. Never pulled back, but hope you amassed a decent sized position.

[Prudent Capitalist]

Another new high today above $26. AXGN also rang the bell on the exchange today. My avg. cost per share here is just below $3.50. Sweet!

[dog turd cannon]

It is possible. I've had shares since 2.50.

[Prudent Capitalist]

+13.2% and a new high at $23.80 today following the earnings release. Hope you still have those 4k shares fredo!

[Prudent Capitalist]

I had seen some predictions here that AXGN would eventually trade at $100 per share, and I am starting to believe that is possible long term. Great things happening here with this company right now, and I am only sick I did not buy more. I have quite a bit, but it is never enough with a stock like this.

[dog turd cannon]

Up over 700% since this... amazing.

[Prudent Capitalist]

More new 52-week highs for AXGN this week.

[Prudent Capitalist]

Setting new 52-week highs all the time now. Another new one at $13.73 earlier this am. AXGN is a very special holding to put away and forget about, as it will be worth many times what it is today in time.

[MinnieM]

It keeps making new highs...

[Prudent Capitalist]

New 52-week high every day here lately.

[Prudent Capitalist]

Nice new closing high here today for AXGN.

[Prudent Capitalist]

New 52-week high here today at $11.45

[Prudent Capitalist]

And still holding up strong here.

[Prudent Capitalist]

New 52-week high at $11 today!

[Prudent Capitalist]

+4.5% here today, and much more room to run to the upside. The gains for AXGN just keep coming.

[Prudent Capitalist]

AXGN stetting new highs and poised for new legs up going forward.

[Prudent Capitalist]

Great updated higher revenue projections out this am from AXGN. Always knew this one was an ultimate winner.

[Prudent Capitalist]

New 52-week high today, and great prospects going forward.

[Prudent Capitalist]

$10 now, and poised to go much higher based on early updated revenue predictions for Q4 and 2017

[jrstu]

Dilution.........
I've been trading/investing for over 18 years. I can't specifically recall a stock that I owned that acted so well after a dilution announcement.
AXGN may turn into something very special.

[Prudent Capitalist]

$9.54 now. Nice surge upward this am. Not seeing a pullback in the future here.

[Prudent Capitalist]

Nice to see AXGN close above $9 again.

[Prudent Capitalist]

Bumping up near another new high here today.

[Prudent Capitalist]

New all time high today for AXGN above $9. Doesn't look like a pullback is in the cards, but who knows. I have plenty of shares here acquired in $3 - $4 range, but wish I had a ton more. Not selling any shares here, as the upside is huge long term, IMO.

[fredo47]

I bought 4K shares the first trading day after seeing Axogen in the 2015 Rose Bowl Parade on New Year's Day. I have great hopes for the future of AXGN. If it pulls back I'll sell some other "stuff" add a few more shares.

[Prudent Capitalist]

Agree. And, with surge upward in revenue and prospects going forward at this stage with this entity, this is a strong growth and momentum story and play right now.

[investorpaul]

Looks like big money is not selling. Low % on low volume means price manipulation. Big money have been net holders. This means long term growth in the stock.

[Prudent Capitalist]

Fair points, but I am a holder here. This has been kind of a sleeper, but if more folks knew the story this Board would be much more active, IMO.

[investorpaul]

Whenever you see short % above 45 for 2 consecutive days is you que to load up. It happened in June and it happened just a few days ago.

http://www.shortanalytics.com/index2.php